# CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06128044** · PHASE1 · TERMINATED · sponsor: **Caribou Biosciences, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory

## Interventions

- **DRUG:** CB-012

## Key facts

- **NCT ID:** NCT06128044
- **Lead sponsor:** Caribou Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-08
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Sponsor Decision - Pipeline Reprioritization
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128044, "CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06128044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*